Lyell Immunopharma Inc (LYEL) — Cash Flow Reinvestment Rate

Latest as of December 2019: 10.70x

Lyell Immunopharma Inc (LYEL) has a Cash Flow Reinvestment Rate of 10.70x as of December 2019, reinvesting $422.43 Million (capex $16.05 Million plus investments $-406.39 Million) from operating cash flow of $39.47 Million. See LYEL FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

10.70x
(Capex + Investments) / Operating CF

Total Reinvested

$422.43 Million
Capex + Investments

Operating Cash Flow

$39.47 Million
USD

Capital Expenditures

$16.05 Million
USD

Lyell Immunopharma Inc Cash Flow Reinvestment Rate (2019–2019)

Historical reinvestment intensity for Lyell Immunopharma Inc across 1 annual periods. For the full cash flow conversion analysis, see LYEL operating cash flow.

Annual Cash Flow Reinvestment Rate for Lyell Immunopharma Inc (2019–2019)

Year-by-year capital reinvestment analysis for Lyell Immunopharma Inc. See LYEL free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2019 10.70x $422.43 Million $39.47 Million $16.05 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow